Johnson & Johnson
- JNJ
- NYSE
- Consumer Products
- Latest 86.82
- Currency US$
- Change -0.39
- Percent Change -0.447 %
- Volume 10,390,046
- Fri May 24, 2013 4:01 PM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 86.80
- Previous Close 87.21
- High 87.03
- Low 86.49
- Bidx0 86.64
- Askx0 86.99
- 52-week High 05/22 89.99
- 52-week Low 06/01 61.71
- Beta 0.499
- Market Cap 242,839.01M
- EPS 5.18
- P/E 16.76
- Forward P/E 15.021
- PEG 2.62
- Annual Dividend 2.64
- Yield 3.041
News
- Analysis: Drugmakers face more scrutiny of discordant U.S. prices
- PRESS DIGEST - Wall Street Journal - May 10
- Gastric banding: Pros and cons of Christie's surprising choice
- UPDATE 2-Baxter's Alzheimer's disease drug fails in late-stage trial
- MARKET PULSE-Cliffs, Apollo Global, BMC, Intel, Yum, Tyson Foods
- Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
- Cordis Showcases Cardiovascular Innovations at EuroPCR 2013
- Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH™ Catheter
- First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ™ Pulmonary Vein Isolation System™ in the Treatment of Paroxysmal Atrial Fibrillation
- Biosense Webster Showcases Cutting Edge Innovation and Leadership in AF Ablation at HRS Annual Scientific Sessions 2013
Financials & Calendars
- Sales $68,590,000,000
- Earnings $10,440,000,000
- Return on Equity 15.86%
- Cash Flow --
- Cash $14,855,000,000
- Current Ratio 2.10
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $121,536,000,000
- Liabilities $54,681,000,000
- Liabilities-to-Equity Ratio 0.82
Price Ratios
- Price to Sales 3.54
- Price to Book 3.63
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Apr 16 | $1.41 | Jul 16 | $1.40 |
| Surprises | Apr 16 | 2.13% | n/a | n/a |
| Dividends | May 23 | $0.66 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 25, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Officers
- A. Gorsky Chairman;Chief Executive Offic
- D. J. Caruso Chief Financial Officer
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
ONE JOHNSON & JOHNSON PLZNEW BRUNSWICK, NJ
08933
Phone: (732)-524-2455
Fax: (732)-2140332
Ideas & Discussion
Live Discussion of JNJ on StockTwits